“…83,84 Similar outcomes have been seen in smaller institutional series as well, with multilumen and strut applicators demonstrating the potential for improved toxicity profiles. [85][86][87][88][89][90] Outcomes for patients with ductal carcinoma in situ (DCIS) treated with applicator brachytherapy have been evaluated; although smaller studies suggested potentially increased rates of IBTR, the MammoSite Registry data demonstrated low rates of local recurrence in patients with DCIS. 84,91 Although traditionally delivered in 8 to 10 fractions over 4 to 5 days, shorter regimens with applicator brachytherapy have been evaluated.…”